Abstract： Objective:To analyze the clinical efficacy and safety of topiramate high-dose shock therapy in the treatment of children with epilepsy.Methods:A total of 86 children with pediatric epilepsy who were admitted to the Pediatrics of Gaoming District People′s Hospital from May 2015 to May 2019 were selected, aged 4 to 12 years old, and the age range was(8.06±0.62)years old.The children were randomly divided into the high-dose treatment group and the low-dose treatment group, with 43 cases in each group.Patients in the high-dose treatment group were treated with high-dose topiramate shock, and patients in the low-dose treatment group were treated with low-dose topiramate shock.Both groups were treated for 12 weeks.Clinical treatment effect, verbal intelligence quotient(VIQ), full intelligence quotient(FIQ)score and adverse reactions(paresthesia, distraction, nausea and dizziness)were compared between the two groups.Results:The clinical effectiveness of the high-dose treatment group[95.3%(41/43)]was significantly higher than that of the low-dose treatment group[69.8%(30/43)], and the difference was statistically significant( P<0.05). There was no significant difference in VIQ and FIQ scores between the two groups of children before treatment( P>0.05); both VIQ[(108.26±6.85)points]and FIQ scores[(109.26±3.64)points]of the high-dose treatment group after treatment was significantly higher than the low-dose treatment group[(96.85±1.62)points, (100.05±2.84)points], and the difference was statistically significant( P<0.05). There was no significant difference in the incidence of adverse reactions between the high-dose treatment group and the low-dose treatment group( P>0.05). Conclusion:High-dose topiramate shock treatment for pediatric epilepsy can effectively reduce the number of seizures, improve children′s cognitive function, and less adverse reactions, it is worthy of clinical application.